全文获取类型
收费全文 | 41337篇 |
免费 | 3172篇 |
国内免费 | 1205篇 |
专业分类
耳鼻咽喉 | 191篇 |
儿科学 | 974篇 |
妇产科学 | 516篇 |
基础医学 | 6379篇 |
口腔科学 | 865篇 |
临床医学 | 2865篇 |
内科学 | 6400篇 |
皮肤病学 | 705篇 |
神经病学 | 3505篇 |
特种医学 | 618篇 |
外国民族医学 | 5篇 |
外科学 | 3281篇 |
综合类 | 5561篇 |
现状与发展 | 4篇 |
预防医学 | 1958篇 |
眼科学 | 495篇 |
药学 | 6342篇 |
4篇 | |
中国医学 | 1972篇 |
肿瘤学 | 3074篇 |
出版年
2024年 | 90篇 |
2023年 | 790篇 |
2022年 | 1957篇 |
2021年 | 1821篇 |
2020年 | 1387篇 |
2019年 | 1546篇 |
2018年 | 1527篇 |
2017年 | 1418篇 |
2016年 | 1285篇 |
2015年 | 1360篇 |
2014年 | 2220篇 |
2013年 | 2445篇 |
2012年 | 2032篇 |
2011年 | 2468篇 |
2010年 | 1955篇 |
2009年 | 1990篇 |
2008年 | 1994篇 |
2007年 | 1771篇 |
2006年 | 1643篇 |
2005年 | 1534篇 |
2004年 | 1443篇 |
2003年 | 1253篇 |
2002年 | 1083篇 |
2001年 | 819篇 |
2000年 | 797篇 |
1999年 | 697篇 |
1998年 | 562篇 |
1997年 | 574篇 |
1996年 | 501篇 |
1995年 | 467篇 |
1994年 | 401篇 |
1993年 | 291篇 |
1992年 | 241篇 |
1991年 | 246篇 |
1990年 | 185篇 |
1989年 | 155篇 |
1988年 | 167篇 |
1987年 | 132篇 |
1986年 | 143篇 |
1985年 | 288篇 |
1984年 | 304篇 |
1983年 | 239篇 |
1982年 | 269篇 |
1981年 | 214篇 |
1980年 | 198篇 |
1979年 | 181篇 |
1978年 | 135篇 |
1977年 | 94篇 |
1976年 | 103篇 |
1975年 | 91篇 |
排序方式: 共有10000条查询结果,搜索用时 15 毫秒
1.
目的探究老年胃癌患者术前血清白细胞介素6 (IL-6)、胃蛋白酶原(PG)Ⅰ、Ⅱ及PG-Ⅰ/Ⅱ比值在患者预后评估中的意义。方法选择2016年1月—2017年1月南通大学附属海安医院收治的101例外科手术治疗的老年胃癌患者为研究对象。收集患者的临床病理资料,检测血清IL-6和PG-Ⅰ/Ⅱ水平。以全因死亡为随访终点,使用Kaplan-Meier曲线明确患者预后与各指标间的关系。结果受试者工作特征曲线提示,IL-6、PG-Ⅰ和PG-Ⅰ/Ⅱ比值在最佳切割值为10.23pg/mL、30.65μg/L和2.44时,可评估患者的预后,而PG-Ⅱ则无法评估患者的预后。与IL-6≤10.23pg/mL组相比,IL-6> 10.23pg/mL组的肿瘤细胞分化更差、TNM分期Ⅲ期比例明显升高。Kaplan-Meier曲线结果表明,IL-6> 10.23pg/mL组的中位生存期显著短于IL-6≤10.23pg/mL组(28个月vs47个月,P<0.001);PG-Ⅰ≤30.65μg/L组的中位生存期显著短于PG-Ⅰ>30.65μg/L组(34个月vs49个月,P=0.008);PG-Ⅰ/Ⅱ≤2.44组的中位生存期显著短于PG-Ⅰ/Ⅱ> 2.44组(29个月vs56个月,P=0.02)。多因素Cox回归分析表明,肿瘤分化程度、TNM分期、IL-6及PG-Ⅰ/Ⅱ比值是影响患者生存率的独立危险因素。结论术前检测IL-6及PG-Ⅰ/Ⅱ比值有助于评估老年胃癌患者的预后。 相似文献
2.
《Survey of ophthalmology》2023,68(5):940-956
Congenital aniridia is a panocular disorder that is typically characterized by iris hypoplasia and aniridia-associated keratopathy (AAK). AAK results in the progressive loss of corneal transparency and thereby loss of vision. Currently, there is no approved therapy to delay or prevent its progression, and clinical management is challenging because of phenotypic variability and high risk of complications after interventions; however, new insights into the molecular pathogenesis of AAK may help improve its management. Here, we review the current understanding about the pathogenesis and management of AAK. We highlight the biological mechanisms involved in AAK development with the aim to develop future treatment options, including surgical, pharmacological, cell therapies, and gene therapies. 相似文献
3.
4.
6ee;684;603b;结近年6765;股骨6c;子间骨6298;在稳定6027;重建65b9;62;684;6982;念6f14;Ա6;与研ާ6;进展。65b9;6cd5;67e5; 605;6fd;内֑6;6f8;关6587;献ק6;结合自身经验,从股骨6c;子间骨6298;684;解ԥ6;特点、稳定型骨6298;与不稳定型骨6298;Ԡ6;类、稳定6027;复位与不稳定6027;复位、672f;中加压初始稳定与672f;后6ed1;动二6b21;稳定、内6fa;定672f;后稳定6027;评估、65e9;671f;下地站立负重等65b9;62;进行603b;结Ԡ6;6790;。结679c;股骨6c;子间骨6298;发生于股骨颈干骺端6c;6362;区,具6709;天ܓ6;684;内翻不稳定倾向。骨6298;复位质量662f;影响后续内6fa;定r69;安653e;684;6700;重要前63d0;6e0;素。判65ad;骨6298;复位质量6709;对线和对位两65b9;62;,对线采用 Garden 6307;6570;;在对位65b9;62;, 68f;着6ae;质对位݀6;念(6b63;6027;、中6027;、负6027;)684;63d0;出,特别强调前内侧6ae;质684;6f8;互砥住652f;6491;(解ԥ6;、6b63;6027;),662f;获得骨6298;稳定6027;复位684;关键,而不再强调后内侧小6c;子骨块684;作用。672f;后影像[66;684;稳定6027;评Ԡ6;为65e9;671f;下地站立负重63d0;供Ө6;量Ա6;6307;6807;。Ӵ6;672f;中684;前内侧6ae;质652f;6491;复位,在672f;后头颈骨块6ed1;动获得二6b21;稳定684;过程中,仍6709;6ae;质对位丢失现61;,需研ާ6;ԗ6;危 669;6e0;素和 632;范63aa;65bd;。结论股骨6c;子间骨6298;在Խ6;得6f;好对线684;基础上,只要获得Ө6;前内侧6ae;质684;6f8;互砥住和652f;6491;,ק6;用内6fa;定668;68b0;维6301;住,就获得Ө6;672f;后稳定6027;。672f;后稳定6027;评Ԡ6;优6f;者,可以安Q68;地65e9;671f;下地负重、站立行走6d3b;动。 相似文献
5.
目的:探讨D6S1043、D12S391基因座的基因多态性对主动攻击行为的影响。方法:应用聚合酶链反应技术结合毛细管电泳法对114例男性主动攻击行为者(研究组)及120名健康男性(对照组)进行D6S1043、D12S391基因座的基因型及等位基因检测,分析D6S1043、D12S391基因座多态性与主动攻击行为的相关性。结果:研究组D6S1043基因座中12~19基因型频率(13.16%)明显高于对照组(1.67%)(P0.05);两组等位基因频率差异无统计学意义;两组D12S391基因座的基因型及等位基因频率差异无统计学意义。结论:D6S1043基因座中12~19基因型可能主动攻击行为有关。 相似文献
6.
目的探究N6-甲基腺嘌呤(m6A)去甲基化酶ALKBH5与弱精症的相关性。方法收集精液标本30份,包括弱精症患者与健康者精液标本各15份,密度梯度离心纯化精子,使用液相色谱与质谱联用(LC-MS/MS)检测精子RNA的m6A水平,使用实时荧光定量PCR法检测ALKBH5相对表达水平。结果弱精症患者m6A水平明显高于健康者,ALKBH5相对表达水平低于健康者,差异均有统计学意义(P<0.05)。精子活动度参数相关性分析结果显示,ALKBH5相对表达水平与前向运动精子数和非前向运动精子数呈正相关(r=0.512、0.377,P<0.05),与不动精子数呈负相关(r=-0.497,P<0.05);m6A与前向运动精子数和非前向运动精子数呈负相关(r=-0.442、-0.425,P<0.05),与不动精子数呈正相关(r=0.528,P<0.05)。结论在弱精症患者中,m6A及其去甲基化酶ALKBH5与精子活动度具有相关性。 相似文献
7.
《Clinical genitourinary cancer》2022,20(3):e217-e226
Background: Intraductal carcinoma and cribriform (IDC/C) tumor features are well-established prognosticators of biochemical recurrence (BCR), metastasis, and prostate cancer (PCa)-specific mortality. However, approximately 70% of PCa patients undergoing a radical prostatectomy are IDC/C negative, yet up-to 20% of these patients progress and experience BCR. Thus, tumor histopathologic characteristics such as IDC/C alone are limited in their ability to predict disease progression. Conversely, several nomograms such as Cancer of the Prostate Risk Assessment-Surgery (CAPRA-S) have been developed to aid in the prognostication of BCR, but not yet widely applied in clinical settings. Materials and methods: In this study, we assessed the combined prognostic utility of IDC/C, and CAPRA-S for BCR in 3 PCa patient cohorts. Results: CAPRA-S+IDC/C improved the predictive accuracy of BCR in all 3 cohorts (P < .001). Specifically, among IDC/C negative cases, CAPRA-S improved the prognostication of BCR in low-risk (Cohort 1; P < .001, Cohort 2; P < .001, Cohort 3; P = .003), intermediate (Cohort 1; P < .001, Cohort 2; P = .006, Cohort 3; P = .03) and high-risk (Cohort 1-3; P < .001) patients. Conversely, IDC/C improved the prognostication of BCR among CAPRA-S low-risk (Cohorts 1; P < .001 and Cohort 3; P = .003) patients. Conclusion: Our results suggest the investigation of histopathological IDC/C features in CAPRA-S low-risk patients and conversely, nomogram CAPRA-S among IDC/C negative patients improves the identification of patients likely to experience BCR, which would otherwise be missed through current assessment regimens. These patients can be offered more intensive monitoring and adjuvant therapies upfront to circumvent the development of recurrent cancer or overtreatment at the time of surgery. 相似文献
8.
6-Mercaptopurine (6-MP) is commonly used for treatment of acute lymphoblastic leukemia (ALL). The incidence of hematotoxicity caused by this drug is quite high in Asians even using a standard low dosage regimen. The present study was aimed to elucidate the impact of thiopurine S-methyltransferase (TPMT), a nucleoside diphosphate-linked moiety X-type motif 15 (NUDT15), inosine triphosphatase (ITPA) and ATP Binding Cassette Subfamily C Member 4 (ABCC4) polymorphisms on hematotoxicity in pediatric patients who received a standard low starting dose of 6-MP. One hundred and sixty-nine pediatric patients were enrolled and their genotypes were determined. Patients who carried NUDT1513 and NUDT1512 genotypes were at a 10–15 fold higher risk of severe neutropenia than those of the wild-type during the early months of the maintenance phase. Risk of neutropenia was not significantly increased in patients with other NUDT15 variants as well as in patients with TPMT, ITPA or ABCC4 variants. These results suggest that NUDT15 polymorphisms particularly, NUDT1513 and NUDT1512, play major roles in 6-MP-induced severe hematotoxicity even when using a standard low dosage of 6-MP and genotyping of these variants is necessary in order to obtain precise tolerance doses and avoid severe hematotoxicity in pediatric patients. 相似文献
9.
《Clinical Lymphoma, Myeloma & Leukemia》2022,22(8):608-617
BackgroundConsiderable progress has been made in therapeutic options for multiple myeloma (MM). Understanding the current landscape of MM treatment options and associated outcomes in the real world is important in providing key insights into clinical and knowledge gaps which could be targeted for further optimization.MethodsThe Canadian Myeloma Research Group Database (CMRG-DB) is a prospectively maintained disease-specific database with >7000 patients. The objective of this study was to describe the trends in the treatment landscape and outcomes including early mortality, time to next treatment, and overall survival (OS) in each line of treatment stratified by autologous stem cell transplant (ASCT) receipt among newly-diagnosed MM patients in Canada between 2007 and 2018.ResultsA total of 5154 patients were identified among which 3030 patients (58.8%) received an upfront ASCT and 2124 (41.2%) did not. At diagnosis, the median age was 64 years and 58.6% were males. Bortezomib and lenalidomide were most frequently used (>50%) in first and second-line treatment respectively among both the ASCT and non-ASCT cohort. The median OS was 122.0 months (95% Cl 115.0-135.0 months) and 54.3 months (95% CI 50.8-58.8 months) for the ASCT and non-ASCT cohort respectively with an incremental decrease in OS in each subsequent line of treatment.ConclusionWe present the largest study to date in the Canadian landscape showing the characteristics, therapy usage, and outcomes among MM patients. This information will be critical in benchmarking current outcomes and provide key insight into areas of unmet needs and gaps for improvement of MM patients nationally. 相似文献
10.